医学教育

订阅

MedSci主页 / 所有栏目 / 医学教育

如果做某一实验结果与疾病之间相关性研究的话，研究类型设定为病例对照研究是否更合适，如果纳入文章数量不多，是否可以加入队列研究和rct干预前的相关数据

2021-05-31 MedSci原创 MedSci原创

关注

如果做某一实验结果与疾病之间相关性研究的话，研究类型设定为病例对照研究是否更合适，如果纳入文章数量不多，是否可以加入队列研究和rct干预前的相关数据

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837942, encodeId=6570183e9423c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Apr 11 17:46:01 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984145, encodeId=d312198414545, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 05 00:46:01 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975924, encodeId=875019e592470, content=<a href='/topic/show?id=c1b1e342877' target=_blank style='color:#2F92EE;'>#研究类型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73428, encryptionId=c1b1e342877, topicName=研究类型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sun Mar 20 04:46:01 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756175, encodeId=f1a71e56175eb, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Thu Nov 25 02:46:01 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775564, encodeId=004b1e755640f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon May 02 06:46:01 CST 2022, time=2022-05-02, status=1, ipAttribution=)]
    2022-04-11 shenxlcyp

    #相关性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1837942, encodeId=6570183e9423c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Apr 11 17:46:01 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984145, encodeId=d312198414545, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 05 00:46:01 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975924, encodeId=875019e592470, content=<a href='/topic/show?id=c1b1e342877' target=_blank style='color:#2F92EE;'>#研究类型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73428, encryptionId=c1b1e342877, topicName=研究类型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sun Mar 20 04:46:01 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756175, encodeId=f1a71e56175eb, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Thu Nov 25 02:46:01 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775564, encodeId=004b1e755640f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon May 02 06:46:01 CST 2022, time=2022-05-02, status=1, ipAttribution=)]
    2022-02-05 fengyi812

    #病例对照研究#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1837942, encodeId=6570183e9423c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Apr 11 17:46:01 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984145, encodeId=d312198414545, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 05 00:46:01 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975924, encodeId=875019e592470, content=<a href='/topic/show?id=c1b1e342877' target=_blank style='color:#2F92EE;'>#研究类型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73428, encryptionId=c1b1e342877, topicName=研究类型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sun Mar 20 04:46:01 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756175, encodeId=f1a71e56175eb, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Thu Nov 25 02:46:01 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775564, encodeId=004b1e755640f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon May 02 06:46:01 CST 2022, time=2022-05-02, status=1, ipAttribution=)]
    2022-03-20 lq1767

    #研究类型#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1837942, encodeId=6570183e9423c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Apr 11 17:46:01 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984145, encodeId=d312198414545, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 05 00:46:01 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975924, encodeId=875019e592470, content=<a href='/topic/show?id=c1b1e342877' target=_blank style='color:#2F92EE;'>#研究类型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73428, encryptionId=c1b1e342877, topicName=研究类型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sun Mar 20 04:46:01 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756175, encodeId=f1a71e56175eb, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Thu Nov 25 02:46:01 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775564, encodeId=004b1e755640f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon May 02 06:46:01 CST 2022, time=2022-05-02, status=1, ipAttribution=)]
    2021-11-25 xugc

    #病例对照#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1837942, encodeId=6570183e9423c, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Apr 11 17:46:01 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984145, encodeId=d312198414545, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 05 00:46:01 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975924, encodeId=875019e592470, content=<a href='/topic/show?id=c1b1e342877' target=_blank style='color:#2F92EE;'>#研究类型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73428, encryptionId=c1b1e342877, topicName=研究类型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sun Mar 20 04:46:01 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756175, encodeId=f1a71e56175eb, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Thu Nov 25 02:46:01 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775564, encodeId=004b1e755640f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon May 02 06:46:01 CST 2022, time=2022-05-02, status=1, ipAttribution=)]
    2022-05-02 amyloid

    #对照#

    0